BMI View: We remain largely pessimistic about Belarus?s pharmaceutical market development, at leastin the short term. The government remains committed to boosting domestic pharmaceutical output overthe coming years, with authorities in manufacturing joint venture (JV) discussions with a number ofcountries. However, the devalued ruble, high inflation and weak household consumption will continue toconstrain both the volume and value of medicines consumed in Belarus. We also note increased politicaland economic risks, as the country aligns itself away from the European Union.Headline Expenditure Projections:?? Pharmaceuticals: BYR3,598bn in 2011 (US$692mn) to BYR5,6...
No comments:
Post a Comment